You, M., Xing, P., Li, J. (2026). High-dose furmonertinib in
                    <i>EGFR</i>
                    -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8607